We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Multiple myeloma is a type of blood cancer that originates due to an abnormal proliferation of plasma cells (one type of leukocyte, the body’s defence). These plasma cells can cause bone lesions, growing profusely and causing anaemia. At the same time, they are able to produce immunoglobulins. These are proteins that, in excess, can affect the kidneys and increase the risk of infection.
Multiple myeloma is a type of bone marrow cancer that comes about due to the proliferation of clonal plasma cells and the abnormal production of immunoglobulins (Ig), which are a component of the immune system and can be found in blood and/or urine.
The annual incidence in adults is 4-6 new cases per 100,000 of the population per year, which represents 1% of all cancers and 10% of blood cancers. These figures mean the condition is considered rare. It often affects predominantly older people, with the average being around 70 years.
Excess Ig interferes with the properties of the blood, affecting normal kidney function and increasing the risk of developing infections (as normal Ig are not produced). If there are also excess plasma cells, the bones containing bone marrow may be damaged, with possible fractures and pain. It can also make the normal production of red blood cells, white blood cells and platelets more difficult, leading to increased risk of anaemia, infection and bleeding.
The classic symptoms of myeloma are given by the initials of the affected organs: “CRAB” (Calcium, Renal failure, Anaemia, Bone lesions). These may, however, lead to other symptoms:
In a routine analysis, it is common to find a monoclonal gammopathy, anaemia or to diagnose a fracture after the persistence of bone pain that does not stop with conventional analgesia.
To confirm the diagnosis and establish the extent and treatment needs, a full blood count needs to be conducted with a special protein study, a urine analysis to rule out abnormal protein excretion by the kidneys, a bone marrow aspirate or biopsy to confirm excess plasma cells in the bone marrow (if possible with cytometric and genetic study) and imaging tests to rule out bone lesions.
Treatment of multiple myeloma has changed significantly in the last decade and above all in recent years with the appearance of new drugs and action mechanisms.
The aim of treatment is to control the condition for the longest amount of time possible with minimal side effects and to achieve a good quality of life.
Treatment of multiple myeloma includes drugs that can be classified according to their mechanism of action:
· Proteaosome inhibitors
· IMiDs
· Alkylating agents
· Corticosteroids
· Monoclonal antibodies
As well as the drugs and combinations used, a treatment plan may also take into account the possibility of one (or two) bone marrow transplants.
There is currently an exponential increase in the development of new treatments for multiple myeloma. New drugs are being developed with different mechanisms of action. In some cases, these new drugs or potentially beneficial combinations may be offered as part of clinical trials.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.